<DOC>
	<DOCNO>NCT02628574</DOCNO>
	<brief_summary>This study conduct 2 part ( Part A Part B ) . Subjects â‰¥18 year advance solid tumor enrol study . Dose escalation perform Part A . Cycle 1 data cohort evaluate safety dose-limiting toxicity ( DLTs ) prior dose escalation . Subjects assign cohort order screen complete . Dose depend upon cohort patient enrol cohort dose consecutively ascend dose . Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) identify , expand cohort enrol ( Part B ) .</brief_summary>
	<brief_title>Dose Escalation Study TRX518 Adults With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced Solid Malignancies least 1 measurable lesion , fail respond relapse follow standard treatment decline pursue standard treatment , otherwise stable health ( confirm medical history , physical examination , ECG , screen laboratory test ) . Expected survival least 12 week dose . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Evidence adequate organ function standard laboratory test . All female subject child bear age must either surgically sterile , postmenopausal least 1 year , use acceptable method contraception . Adequate contraception male female subject must use begin screen period least 8 week last dose TRX518 . Hematologic malignancies multiple myeloma . Known , clinically important cardiac respiratory disease Any concomitant serious physical illness cancer ( e.g. , immune deficiency disease , bleed disorder , etc . ) within 1 year prior dose . No history autoimmune disease . Active , uncontrolled infection within 7 day study entry require systemic therapy . Evidence progression central nervous system ( CNS ) metastases symptomatic CNS metastasis within 30 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Stage III IV</keyword>
	<keyword>recurrent</keyword>
	<keyword>refractory</keyword>
	<keyword>solid tumor</keyword>
</DOC>